Session » (0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0692

A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

10:30AM-12:30PM: Abstract Number: 0699

A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0698

A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients

10:30AM-12:30PM: Abstract Number: 0680

Altered miRNA patterns of peripheral blood mononuclear cells show correlations with pulmonary manifestations of systemic sclerosis

10:30AM-12:30PM: Abstract Number: 0673

Association Between Vasoactive-Vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence From a EUSTAR Study

10:30AM-12:30PM: Abstract Number: 0708

Association Of Choroidal Sub-foveal Thickness With Skin Manifestations And Serum Monocyte HDL Ratio In Patients With Systemic Sclerosis-A Case Control Study

10:30AM-12:30PM: Abstract Number: 0691

Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0672

Determinants of Progressive Microstomia in Systemic Sclerosis: Insights from the GENISOS Cohort with a Focus on GI Involvement

10:30AM-12:30PM: Abstract Number: 0689

Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment

10:30AM-12:30PM: Abstract Number: 0700

Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension

10:30AM-12:30PM: Abstract Number: 0687

Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification

10:30AM-12:30PM: Abstract Number: 0702

Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.

10:30AM-12:30PM: Abstract Number: 0676

Engineered glove for the objective assessment of hand dexterity in patients with systemic sclerosis: correlations with clinical features, nailfold videocapillaroscopy, and high frequency skin ultrasonography

10:30AM-12:30PM: Abstract Number: 0681

Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0701

Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort

10:30AM-12:30PM: Abstract Number: 0695

Global Longitudinal, Circumferential, and Radial Strain in Systemic Sclerosis Patients with Left Ventricular Dysfunction

10:30AM-12:30PM: Abstract Number: 0704

Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer

10:30AM-12:30PM: Abstract Number: 0696

Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0693

Impact of X Chromosome Dosage on the Development of Diffuse and Limited Systemic Sclerosis in Klinefelter, Triple X, and Turner Syndromes: A Multicenter Cohort Study

10:30AM-12:30PM: Abstract Number: 0677

Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.

10:30AM-12:30PM: Abstract Number: 0679

Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation

10:30AM-12:30PM: Abstract Number: 0706

Major salivary glands Ultrasound features in a group of patients with systemic sclerosis: a multicentric study

10:30AM-12:30PM: Abstract Number: 0705

Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study

10:30AM-12:30PM: Abstract Number: 0675

Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.

10:30AM-12:30PM: Abstract Number: 0682

Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study

10:30AM-12:30PM: Abstract Number: 0690

Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease

10:30AM-12:30PM: Abstract Number: 0674

Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis

10:30AM-12:30PM: Abstract Number: 0683

Symptom-Based Clustering of Gastrointestinal Involvement in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0709

Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven

10:30AM-12:30PM: Abstract Number: 0685

Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention

10:30AM-12:30PM: Abstract Number: 0678

Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients

10:30AM-12:30PM: Abstract Number: 0671

The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort

10:30AM-12:30PM: Abstract Number: 0688

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study

10:30AM-12:30PM: Abstract Number: 0684

Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)

10:30AM-12:30PM: Abstract Number: 0694

Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod

10:30AM-12:30PM: Abstract Number: 0703

Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023

10:30AM-12:30PM: Abstract Number: 0686

Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring

10:30AM-12:30PM: Abstract Number: 0710

Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies

10:30AM-12:30PM: Abstract Number: 0707

When Can Support Lead to Missed Clinic Appointments in Patients with Systemic Lupus Erythematosus?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].